An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Status:
Recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy
of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who
previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during
participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled
parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302
[NCT03996369] or APD334-210 [NCT04607837]).